A-DROP Score Calculator- Free Pneumonia Severity Assessment Tool

A-DROP Score Calculator – Free Pneumonia Severity Assessment Tool | Super-Calculator.com

JavaScript Required

This A-DROP score calculator requires JavaScript to assess pneumonia severity, classify community-acquired pneumonia as mild, moderate, severe, or extremely severe, and provide JRS guideline-based management recommendations. Please enable JavaScript in your browser to use this free pneumonia severity assessment tool.

A-DROP Pneumonia Severity Score Calculator

Calculate the A-DROP score for community-acquired pneumonia severity assessment. Select each criterion present to generate a Japanese Respiratory Society severity classification, estimated 30-day mortality, and evidence-based management recommendation for outpatient, hospital, or ICU care.

Important Medical Disclaimer

This calculator is provided for informational and educational purposes only. It is not intended to replace professional medical advice, diagnosis, or treatment. Always consult with a qualified healthcare professional before making any medical decisions. The results from this calculator should be used as a reference guide only and not as the sole basis for clinical decisions.

Criteria Present? (Click row to mark)

✓

Age

Male 70+ yrs / Female 75+ yrs

ABSENT

✓

Dehydration

BUN 21 mg/dL or higher, or clinical dehydration

ABSENT

✓

Respiratory Failure

SpO2 90% or lower, or PaO2 60 mmHg or lower

ABSENT

✓

Orientation Disturbance

New-onset confusion or altered mental status

ABSENT

✓

Pressure (Blood)

Systolic blood pressure 90 mmHg or lower

ABSENT

A-DROP Score

Severity

Mild

Risk Spectrum

MILD

MOD

SEV

EXT

▲

Score 0

Score 1-2

Score 3

Score 4-5

Score

0 / 5

About This A-DROP Score Calculator

This A-DROP pneumonia severity score calculator is designed for clinicians, medical students, nurses, and healthcare professionals assessing adults with suspected community-acquired pneumonia (CAP). It calculates the five-parameter A-DROP score – Age, Dehydration (BUN), Respiratory failure (SpO2 or PaO2), Orientation disturbance, and blood Pressure – to produce a total score from 0 to 5 with immediate severity classification into mild, moderate, severe, or extremely severe categories.

The calculator applies the Japanese Respiratory Society (JRS) 2006 A-DROP scoring system, which uses sex-specific age thresholds (male 70 years, female 75 years), a BUN threshold of 21 mg/dL, an SpO2 cutpoint of 90%, and a systolic blood pressure threshold of 90 mmHg. Each criterion panel cycles through three states – unassessed, present, and absent – allowing flexible real-time scoring. Validation studies across multiple patient cohorts report AUC values around 0.83-0.85 for 30-day mortality prediction, comparable to the CURB-65 score.

The visual risk spectrum bar highlights the patient’s position across the four severity zones, while the summary panel displays the score, severity category, estimated 30-day mortality, and JRS guideline-based site-of-care recommendation. The calculator supports outpatient versus hospitalization versus ICU triage decisions in emergency, primary care, and inpatient settings globally.

A-DROP Score Calculator: Pneumonia Severity Assessment for Community-Acquired Pneumonia

Community-acquired pneumonia (CAP) remains one of the most common and potentially life-threatening infectious diseases worldwide, responsible for millions of hospitalizations annually. Accurate severity assessment at the point of initial presentation is critical - it determines whether a patient can be safely managed at home, requires hospital admission, or needs intensive care unit (ICU) level support. The A-DROP scoring system offers clinicians a rapid, validated, and clinically actionable method to stratify pneumonia severity using just five readily available parameters.

Developed by the Japanese Respiratory Society (JRS) and introduced in the 2006 JRS guidelines for community-acquired pneumonia management, A-DROP stands for Age, Dehydration, Respiratory failure, Orientation disturbance, and blood Pressure. It is a modified and refined version of the widely used British Thoracic Society CURB-65 score, adapted to better reflect the clinical characteristics of pneumonia in aging populations. Each of the five criteria contributes one point to the total score, yielding a range of 0 to 5 that maps directly onto four severity categories with corresponding management recommendations.

This calculator and guide provides clinicians, medical students, nurses, and healthcare professionals with a practical tool and comprehensive reference for applying the A-DROP score correctly and interpreting results in the context of current evidence-based pneumonia management.

A-DROP Score Formula

A-DROP Score = A + D + R + O + P (Range: 0 to 5)

A – Age: Male age 70 years or older = 1 point; Female age 75 years or older = 1 point
D – Dehydration: BUN 21 mg/dL or higher (210 mg/L), or clinical dehydration = 1 point
R – Respiratory failure: SpO2 90% or lower, or PaO2 60 mmHg or lower = 1 point
O – Orientation disturbance: Confusion or altered mental status = 1 point
P – (blood) Pressure: Systolic blood pressure 90 mmHg or lower = 1 point

Background: Why Pneumonia Severity Scoring Matters

Pneumonia is a leading cause of infectious disease-related morbidity and mortality globally. In clinical practice, the initial challenge is determining where and how intensively to treat each patient. Under-triaging a severely ill patient to outpatient management risks death; over-triaging a mild case to hospital admission wastes resources and exposes low-risk patients to nosocomial complications including healthcare-associated infections.

Several severity scoring systems have been developed and validated for this purpose. The Pneumonia Severity Index (PSI), also known as the PORT score, was introduced in 1997 and consists of 20 variables including demographic, comorbidity, physical examination, and laboratory findings. While highly accurate, PSI's complexity makes it impractical in many real-world emergency settings. The CURB-65 score, proposed in 2003 by the British Thoracic Society, simplified severity scoring to five easily collected parameters: Confusion, Urea (BUN greater than 7 mmol/L), Respiratory rate (30 or more breaths per minute), Blood pressure (systolic below 90 mmHg or diastolic 60 mmHg or below), and age 65 or older.

The A-DROP score was developed as a Japanese adaptation of CURB-65, recognizing that the average age of CAP patients in Japan and many other countries with aging populations tends to be higher than in Western validation cohorts. By adjusting the age threshold to reflect sex-specific differences in life expectancy and frailty - and replacing the respiratory rate criterion (which requires physical examination) with an objective oxygen saturation threshold - A-DROP maintains simplicity while arguably offering better clinical relevance in settings where pulse oximetry is readily available.

The Five A-DROP Criteria Explained

A - Age

Age is an established independent predictor of pneumonia mortality. The biological rationale is clear: older adults have reduced immune reserve, diminished respiratory muscle strength, impaired mucociliary clearance, and higher rates of comorbid conditions that complicate recovery. A-DROP applies sex-specific age thresholds: 70 years or older for men and 75 years or older for women. This adjustment reflects well-documented differences in longevity and physiological resilience between sexes. Men aged 70 and women aged 75 have broadly comparable levels of functional reserve and vulnerability to serious infection-related outcomes.

Key Point: Sex-Specific Age Thresholds

Unlike CURB-65 which uses a single age threshold of 65 for all patients, A-DROP distinguishes between men (70 years) and women (75 years). This is a deliberate recognition of sex differences in aging physiology and represents one of the key refinements of A-DROP over its predecessor.

D - Dehydration

Blood urea nitrogen (BUN) serves as a proxy for intravascular volume depletion and renal perfusion. A BUN of 21 mg/dL (which equals approximately 7.5 mmol/L) or higher signals significant dehydration, reduced effective circulating volume, or early renal dysfunction - all of which worsen the physiological reserve needed to fight infection. In addition to the BUN threshold, clinical evidence of dehydration (dry mucous membranes, reduced skin turgor, decreased urine output) may be applied when laboratory data is unavailable or borderline. This flexibility makes A-DROP more applicable in resource-limited or point-of-care settings.

Note on BUN units: BUN is reported in mg/dL in the United States and many other countries, but in mmol/L (as urea, not BUN) in the United Kingdom and some other regions. The A-DROP threshold of 21 mg/dL BUN corresponds approximately to a urea of 7.5 mmol/L. Clinicians should confirm the units reported by their laboratory to apply this criterion correctly.

R - Respiratory Failure

Respiratory compromise is the hallmark of pneumonia severity. A-DROP uses an oxygen saturation threshold (SpO2 90% or below by pulse oximetry) or an arterial partial pressure of oxygen (PaO2 60 mmHg or below). These thresholds correspond to the definition of hypoxemic respiratory failure and represent the point at which supplemental oxygen supplementation becomes urgent. The use of pulse oximetry - widely available in most healthcare settings globally - makes this criterion practical and objective. In settings where arterial blood gas analysis is available, PaO2 can alternatively be used, though in most outpatient and emergency triage contexts, SpO2 is the primary measurement.

O - Orientation Disturbance

Altered mental status or confusion in the setting of pneumonia is a powerful indicator of systemic compromise. It may reflect hypoxemia, hypercapnia, sepsis-related encephalopathy, or direct extension of infection. Clinically, this is assessed as new-onset confusion or disorientation that is not explained by pre-existing cognitive conditions such as dementia. Standard assessment tools - including simple orientation questions (person, place, time) or abbreviated mental test scores - can be applied at bedside. Confusion in pneumonia correlates strongly with bacteremia, sepsis, and 30-day mortality across multiple validation studies.

P - (Blood) Pressure

Hypotension, defined as systolic blood pressure of 90 mmHg or below, indicates cardiovascular compromise and early septic shock physiology. In severe pneumonia, hypotension results from a combination of systemic vasodilation (mediated by inflammatory cytokines), myocardial depression, and distributive shock. The presence of hypotension in a pneumonia patient mandates urgent hospitalization and typically indicates the need for IV fluid resuscitation, vasopressor support, and intensive monitoring. This criterion carries one of the strongest associations with mortality in all CAP severity scoring systems.

A-DROP Score Interpretation and Management Recommendations

The A-DROP score maps to four severity categories with clinical management implications that are broadly accepted in international pneumonia management guidelines.

A-DROP Severity Categories

Score 0 - Mild: Outpatient treatment generally appropriate. Mortality risk is very low (approximately 0.3–1%). Oral antibiotics, close follow-up within 24–48 hours.

Score 1–2 - Moderate: Hospital admission recommended. Mortality risk approximately 3–8%. IV or oral antibiotics depending on presentation, monitoring for deterioration.

Score 3 - Severe: Hospital admission required; consider step-down or ICU monitoring. Mortality risk approximately 15–25%. IV antibiotics, oxygen supplementation, close monitoring.

Score 4–5 - Extremely Severe: ICU admission strongly recommended. Mortality risk exceeds 30–55%. IV broad-spectrum antibiotics, aggressive supportive care, consider mechanical ventilation.

Clinical Validation and Predictive Performance

The A-DROP score has been extensively validated across multiple patient populations and clinical settings. The landmark 2008 comparative study by Shindo and colleagues (Respirology, 2008) evaluated 329 CAP patients hospitalized at a single center in Japan and found that A-DROP and CURB-65 had nearly identical discriminatory performance for 30-day mortality, with areas under the receiver operating characteristic (ROC) curve of 0.846 for A-DROP and 0.835 for CURB-65. This strong discriminatory performance across the range of CAP severity makes A-DROP a reliable triage tool.

Multiple subsequent studies confirmed these findings in diverse patient cohorts across Asia, Europe, and other regions. A retrospective study of 1,031 CAP patients in South Korea (Scientific Reports, 2018) found that A-DROP performed comparably to both CURB-65 and PSI, demonstrating its applicability beyond the Japanese population for which it was originally developed. Importantly, several studies have also examined A-DROP's performance specifically in elderly patients - the demographic most commonly affected by CAP - and confirmed its utility even in patients with median ages above 75 years.

The score has also been evaluated in specific pneumonia subtypes. Studies of aspiration pneumonia - a distinct entity increasingly common in elderly and neurologically impaired patients - demonstrated significant associations between A-DROP category and in-hospital mortality, with mortality rates of approximately 2.5% in low-to-moderate categories versus 19.4% in the severe-to-extremely-severe categories. More recently, A-DROP has been applied to COVID-19 pneumonia, where it demonstrated a significant correlation between severity classification and both mortality and mechanical ventilation rates across multiple pandemic waves in Japan.

Comparison with CURB-65 and PSI

Understanding how A-DROP relates to the other major pneumonia severity tools helps clinicians select the most appropriate instrument for their clinical context.

CURB-65 was developed from the British Thoracic Society's large multicenter dataset and uses five dichotomous variables - Confusion, elevated Urea, elevated Respiratory rate, low Blood pressure, and age above 65. A-DROP was modeled on CURB-65 but makes three key modifications: the age threshold is raised and made sex-specific; respiratory rate (a parameter requiring clinical examination) is replaced by oxygen saturation (measurable with a device); and the urea threshold is adjusted to correspond approximately to the same BUN cutpoint in mg/dL units. Studies consistently show that both scores achieve comparable discrimination of CAP severity, with AUC values typically in the range of 0.80–0.85 for 30-day mortality.

PSI remains the most complex scoring system, incorporating 20 variables across patient demographics, comorbidities, physical examination findings, and laboratory and radiographic data. Its complexity makes it impractical in busy emergency or outpatient settings, though electronic health record-based automation can reduce this burden. PSI tends to classify a higher proportion of patients into lower-severity categories than CURB-65 or A-DROP, which can be beneficial for identifying truly low-risk patients for outpatient management but may under-identify some high-risk younger patients with severe physiologic derangement.

Key Point: When to Use A-DROP vs. Other Scores

A-DROP is best suited for settings with access to pulse oximetry and basic laboratory data including BUN. It performs particularly well in elderly patient populations. CURB-65 remains appropriate when BUN is available and respiratory rate measurement is reliable. PSI is preferred when electronic decision support is available and maximum accuracy for lower-risk patient identification is needed. No single score should be used in isolation - clinical judgment must integrate patient framing, comorbidities, social circumstances, and local resources.

Limitations of the A-DROP Score

Despite its validation and clinical utility, A-DROP has several important limitations that clinicians should understand:

Population derivation: A-DROP was developed primarily from Japanese patient cohorts. Although it has been validated in non-Japanese populations, performance may vary in demographic groups with different baseline comorbidity profiles, healthcare access, or microbiological epidemiology.

Does not incorporate comorbidities: Conditions such as chronic obstructive pulmonary disease, heart failure, malignancy, immunosuppression, and diabetes significantly affect pneumonia prognosis but are not captured by A-DROP. In patients with significant comorbid burden, clinical judgment must supplement the numerical score.

Static assessment: A-DROP captures severity at a single point in time. Pneumonia can deteriorate or improve rapidly; serial reassessment is essential, and initial scores should not preclude subsequent escalation of care if the clinical picture worsens.

Aspiration pneumonia: Standard CAP severity scores were not originally developed for aspiration pneumonia, a distinct pathophysiological entity. While studies suggest A-DROP retains some prognostic value in this context, its performance may be different from its use in typical bacterial CAP.

Immunocompromised patients: Patients on immunosuppressive therapy, with HIV infection, on chemotherapy, or post-transplant may not exhibit classic inflammatory responses, potentially underscoring severity on clinical grounds while true physiologic compromise is severe.

BUN availability: While basic metabolic labs are usually available in emergency settings, there may be time delays or unavailability in some resource-limited environments. The provision for clinical dehydration as an alternative to BUN partially addresses this, but introduces subjectivity.

Application in Specific Patient Populations

The A-DROP score finds broad application across diverse clinical contexts, though with some important population-specific considerations.

In elderly patients, A-DROP's sex-specific age thresholds make it particularly relevant. Studies in Japanese, Korean, and European cohorts with median patient ages in the seventh and eighth decades confirm that A-DROP discriminates well across severity grades. In very elderly patients (age 85 or older), even a score of 1–2 should prompt careful consideration of inpatient management given reduced physiologic reserve.

In nursing home and healthcare-associated pneumonia (NHCAP) patients, A-DROP has been formally evaluated and included in the JRS NHCAP guidelines. Performance is broadly maintained, though NHCAP often involves more resistant organisms, which affects antibiotic selection independently of severity scoring.

In younger patients (below the A-DROP age thresholds), a score of 0 may be reassuringly predictive of low risk. However, younger patients with scores of 1 or higher - who by definition have significant physiologic derangement (hypoxia, hypotension, confusion, or severe dehydration) - warrant careful clinical evaluation and often inpatient management despite not meeting the age criterion.

Integration with Clinical Decision-Making

The A-DROP score is designed as a clinical decision support tool, not a replacement for clinical judgment. It provides a standardized framework that structures the assessment of the five most prognostically important variables, reducing variability in severity estimation between clinicians. However, the following principles should guide its application:

First, always consider the full clinical picture. Vital sign trends, work of breathing, patient report of symptoms, vaccination status, antibiotic history, and functional status all bear on appropriate management decisions. A patient with an A-DROP score of 1 who is clearly deteriorating over hours warrants closer monitoring than a stable patient with the same score.

Second, social and support factors matter. Outpatient management for mild CAP requires that the patient has reliable access to medications, follow-up, and a support person who can monitor for deterioration and facilitate return to care if needed. Patients lacking these supports may benefit from brief inpatient observation even with low severity scores.

Third, A-DROP guides site of care, not antibiotic selection. Antibiotic choice in CAP is determined by likely pathogens, local resistance patterns, allergy history, severity, and comorbidities - considerations that are separate from the severity score itself.

Validation Across Diverse Populations

One of the key questions for any scoring system originally developed in a specific national context is its transportability to different populations. A-DROP has been evaluated in patient cohorts from Japan, South Korea, China, Indonesia, and several European countries, consistently demonstrating AUC values for 30-day or in-hospital mortality in the range of 0.75–0.85.

Studies examining racial and ethnic differences in pneumonia outcomes have noted that A-DROP performs comparably to CURB-65 and PSI across East Asian, South Asian, and Western patient cohorts, supporting its use as a general-purpose severity tool. Some studies suggest that BUN thresholds may have slightly different discriminatory properties in populations with different baseline renal function or nutritional status, which is a consideration when applying any BUN-based scoring system to diverse clinical environments.

Unit conversion for BUN: 1 mg/dL BUN = 0.357 mmol/L urea. The A-DROP threshold of 21 mg/dL BUN therefore corresponds to approximately 7.5 mmol/L urea. Some laboratories report urea (as opposed to BUN); clinicians should confirm the reporting convention with their local laboratory.

A-DROP in the Context of COVID-19 Pneumonia

The COVID-19 pandemic prompted evaluation of existing pneumonia severity scores in a novel pathogen context. Multiple studies, including a large analysis of 1,141 COVID-19 pneumonia patients in Japan (Miyashita et al., Journal of Infection and Chemotherapy, 2023), demonstrated that A-DROP retained its discriminatory properties across all five COVID-19 pandemic waves. Mortality rates of 0% (mild), 3.2% (moderate), 20.8% (severe), and 55% (extremely severe) were observed, confirming the score's utility for patient triage even in the context of a novel respiratory virus.

These findings support A-DROP's use as part of initial pneumonia assessment in clinical settings regardless of the specific causative pathogen, while recognizing that specific management decisions (including antiviral therapy, immunomodulation, and infection control) will be pathogen-specific.

Frequently Asked Questions

What does A-DROP stand for?

A-DROP is an acronym for the five clinical criteria used in the scoring system: Age (sex-specific: male 70 or older, female 75 or older), Dehydration (BUN 21 mg/dL or higher, or clinical signs of dehydration), Respiratory failure (SpO2 90% or lower, or PaO2 60 mmHg or lower), Orientation disturbance (confusion or altered mental status), and blood Pressure (systolic 90 mmHg or lower). Each criterion present contributes one point to the total score, which ranges from 0 to 5.

Who developed the A-DROP scoring system?

A-DROP was developed by the Japanese Respiratory Society (JRS) and introduced in the 2006 JRS guidelines for the management of community-acquired pneumonia in adults. It was proposed as a modification of the CURB-65 score developed by the British Thoracic Society in 2003. The primary authors associated with the initial comparative validation studies include Miyashita et al. and Shindo et al., who published validating research in peer-reviewed journals including Respirology and Internal Medicine.

What is the difference between A-DROP and CURB-65?

A-DROP and CURB-65 share a common framework but differ in three key ways. First, A-DROP uses sex-specific age thresholds (male 70, female 75) versus a single threshold of 65 in CURB-65. Second, A-DROP uses oxygen saturation (SpO2 90% or lower) or arterial oxygen tension (PaO2 60 mmHg or lower) as the respiratory criterion, while CURB-65 uses respiratory rate (30 or more breaths per minute). Third, A-DROP's BUN threshold of 21 mg/dL (210 mg/L) differs slightly from CURB-65's urea threshold of 7 mmol/L. Both scores have similar predictive accuracy for 30-day mortality with AUC values around 0.83–0.85.

What is a normal or safe A-DROP score?

An A-DROP score of 0 indicates mild pneumonia with very low short-term mortality risk (typically below 1%). At this score level, outpatient management with oral antibiotics is generally appropriate for patients who are hemodynamically stable, able to take oral medications, have reliable social support and access to follow-up care, and have no serious comorbidities requiring hospitalization. Even with a score of 0, clinical judgment is essential - if the patient's condition is deteriorating, hospital observation may still be warranted.

At what A-DROP score should a patient be hospitalized?

JRS guidelines recommend hospital admission for patients with A-DROP scores of 1 or above. Score 0 allows outpatient management; scores 1–2 indicate moderate severity warranting inpatient admission with standard care; score 3 indicates severe pneumonia requiring hospital admission with consideration of ICU-level monitoring; scores 4–5 indicate extremely severe disease typically requiring ICU admission. However, even patients with score 0 may need hospitalization based on clinical factors including inability to take oral medications, lack of social support, rapid deterioration, or significant comorbidities.

How accurate is A-DROP for predicting mortality?

A-DROP demonstrates good discriminatory accuracy for predicting 30-day mortality in community-acquired pneumonia, with area under the ROC curve (AUC) values typically reported between 0.80 and 0.85 in validation studies. This is comparable to CURB-65 (AUC approximately 0.83) and somewhat lower than PSI (AUC typically 0.85–0.89). However, all these scores are tools to assist clinical decision-making and should not be used as the sole basis for prognosis or management decisions.

Can A-DROP be used for aspiration pneumonia?

A-DROP has been evaluated in aspiration pneumonia and demonstrates an association between score category and in-hospital mortality. A study from Saitama Medical University Hospital found that patients in the severe-to-extremely-severe categories had significantly higher mortality than those in the low-to-moderate categories. However, aspiration pneumonia is considered a distinct pathophysiological entity from bacterial CAP, and standard CAP severity scores may not fully capture the specific risk factors relevant to aspiration pneumonia, such as swallowing dysfunction severity and aspiration volume. Clinical assessment should supplement the score in this context.

What BUN value is used in A-DROP, and what if only urea is reported?

A-DROP uses a BUN threshold of 21 mg/dL (equivalent to 210 mg/L). If your laboratory reports urea in mmol/L rather than BUN in mg/dL, the approximate conversion is: BUN (mg/dL) = Urea (mmol/L) x 2.8. Therefore, the A-DROP BUN threshold of 21 mg/dL corresponds approximately to a urea of 7.5 mmol/L. Always confirm the units and conversion factors with your specific laboratory's reporting convention, as this may vary. Some laboratories in the UK and Commonwealth countries report urea rather than BUN.

Is SpO2 or PaO2 used for the respiratory criterion?

A-DROP accepts either SpO2 (peripheral oxygen saturation by pulse oximetry) or PaO2 (partial pressure of oxygen from arterial blood gas). The threshold for SpO2 is 90% or lower; for PaO2 it is 60 mmHg or lower. In most clinical settings, SpO2 is used as the primary measurement because pulse oximetry is non-invasive, immediately available, and widely accessible. Arterial blood gas analysis may be used when pulse oximetry is unreliable (such as in patients with poor peripheral perfusion, nail polish, or motion artifact) or when more comprehensive gas exchange information is needed.

Why does A-DROP use different age thresholds for men and women?

The sex-specific age thresholds in A-DROP reflect documented biological differences in aging between men and women. Women generally have longer life expectancy and maintain physiologic reserve longer than men of the same chronological age. The JRS recognized that using a single age threshold would systematically underestimate the physiologic age of men or overestimate the risk of women. By setting the threshold at 70 for men and 75 for women, A-DROP attempts to apply equivalent physiologic risk thresholds to both sexes, rather than applying identical numerical cutoffs.

How is confusion assessed for the orientation disturbance criterion?

Orientation disturbance in A-DROP refers to new-onset confusion or altered mental status. Clinically, this is typically assessed by testing orientation to person, place, and time, or using a brief validated cognitive tool such as the Abbreviated Mental Test (AMT) or the Short Confusion Assessment Method. Importantly, the confusion should be new or acute in onset relative to the patient's baseline cognitive function. Patients with pre-existing dementia may be challenging to assess; in these cases, collateral history from caregivers regarding any acute change from baseline is valuable. Any acute deterioration from baseline mental status should be considered orientation disturbance for scoring purposes.

Can A-DROP be used for hospital-acquired pneumonia (HAP)?

A-DROP was specifically designed and validated for community-acquired pneumonia (CAP). The JRS has also incorporated it into nursing and healthcare-associated pneumonia (NHCAP) guidelines with some modification. Hospital-acquired pneumonia (HAP) and ventilator-associated pneumonia (VAP) involve different pathogen profiles, host risk factors, and clinical contexts, and A-DROP has not been formally validated in these settings. For HAP and VAP, disease-specific assessment tools and institutional infection control protocols are more appropriate. That said, the physiologic parameters within A-DROP (oxygenation, blood pressure, mental status) remain clinically relevant regardless of pneumonia classification.

Does A-DROP work for immunocompromised patients?

Immunocompromised patients - including those with HIV, on chemotherapy, receiving immunosuppressive therapy post-transplant, or with hematologic malignancies - may not generate the typical inflammatory response to pneumonia. This means they may appear clinically milder than their actual degree of tissue infection warrants. Standard CAP severity scores including A-DROP were not developed or validated specifically in immunocompromised populations, and they may underestimate severity in these patients. For immunocompromised patients with pneumonia, a lower threshold for hospitalization, aggressive diagnostic workup, and early infectious disease or respiratory specialty consultation is generally recommended regardless of the numerical severity score.

What mortality rates are associated with each A-DROP score?

Reported mortality rates vary across studies, but typical estimates for 30-day or in-hospital mortality are: Score 0 (mild): approximately 0.3–1%; Scores 1–2 (moderate): approximately 3–8%; Score 3 (severe): approximately 15–25%; Scores 4–5 (extremely severe): approximately 30–55%. These figures should be interpreted as population-level estimates rather than individual predictions. The specific mortality rate observed in any patient cohort will depend on local factors including age distribution, comorbidity burden, causative organisms, antibiotic treatment quality, and level of available supportive care.

Should A-DROP be used in children or adolescents?

No. A-DROP was developed and validated exclusively in adult patients. The scoring criteria, including age thresholds and physiologic parameters, are calibrated for adult physiology. Pediatric pneumonia has different causative organisms, clinical presentations, physiologic norms, and management pathways than adult CAP. For children with pneumonia, age-appropriate scoring systems such as the Pediatric Pneumonia Severity Index or British Thoracic Society pediatric pneumonia guidelines should be used instead.

Can I use A-DROP for follow-up assessment during hospitalization?

A-DROP was designed as an admission-time triage and severity classification tool, not a serial monitoring instrument. However, the physiologic parameters it assesses - oxygenation, blood pressure, mental status, and kidney function - are standard components of ongoing clinical monitoring during hospitalization. Clinicians routinely reassess these parameters as part of standard inpatient care. If a patient's A-DROP parameters worsen during admission, this should prompt consideration of escalation of care, even if the initial score was low. The score provides a structured framework for this reassessment, though it was not formally validated as a serial tool.

What antibiotic regimen does A-DROP recommend?

A-DROP is a severity classification tool, not an antibiotic selection guide. It determines where and how intensively to manage pneumonia (outpatient vs. inpatient vs. ICU), but antibiotic choice is determined separately based on: likely causative organisms given the clinical and epidemiological context, local antimicrobial resistance patterns, patient allergy history, prior culture data, severity of illness, and applicable clinical practice guidelines from infectious disease and respiratory medicine societies. National and regional pneumonia management guidelines (such as those from the American Thoracic Society, European Respiratory Society, or British Thoracic Society) provide detailed antibiotic recommendations stratified by severity.

How was A-DROP validated in COVID-19 pneumonia?

A large Japanese study (Miyashita et al., 2023) analyzed 1,141 patients with COVID-19 pneumonia across five pandemic waves and found that A-DROP classification significantly correlated with both mortality and mechanical ventilation rates in each wave, despite differences in variants and available treatments. Mortality rates of 0%, 3.2%, 20.8%, and 55% were observed for mild, moderate, severe, and extremely severe A-DROP categories respectively. The Cochran-Armitage trend test confirmed a statistically significant dose-response relationship. This supports A-DROP as a valid initial severity assessment tool for COVID-19 pneumonia alongside disease-specific clinical judgment.

Is A-DROP used internationally or only in Japan?

While A-DROP was developed by the Japanese Respiratory Society and is most widely used in Japan, it has been evaluated and applied clinically in South Korea, China, Indonesia, and several other countries. International studies have generally confirmed its validity and comparability to CURB-65 and PSI in diverse patient cohorts. It is referenced in some international clinical guidelines as an alternative to CURB-65. However, CURB-65 and PSI remain more widely cited in Western clinical practice guidelines from organizations such as the American Thoracic Society, European Respiratory Society, and British Thoracic Society.

What is the clinical significance of "dehydration" in A-DROP if BUN is unavailable?

When laboratory data is unavailable or pending, the A-DROP dehydration criterion can be assessed clinically using physical examination findings indicative of significant volume depletion: dry mucous membranes, reduced skin turgor, sunken eyes, decreased urine output, and orthostatic hypotension. This flexibility was intentional in the design of A-DROP to allow its application in resource-limited settings or when laboratory results are delayed. However, clinical assessment of dehydration is subjective and less reproducible than a BUN measurement, so laboratory confirmation is preferred when feasible.

Does a score of 3 always require ICU admission?

A score of 3 indicates severe pneumonia and requires hospitalization, but does not automatically mandate ICU admission in all guidelines. The JRS recommendations suggest hospital admission with consideration of higher-level monitoring or step-down unit care for score 3. ICU admission is most strongly recommended for scores 4–5 (extremely severe). However, local institutional criteria for ICU admission, bed availability, patient preferences, presence of specific high-risk features (such as bilateral infiltrates, need for vasopressors, or progressive hypoxemia despite supplemental oxygen), and clinical trajectory should all inform the decision about ICU referral. Score alone should never be the sole determinant of care level.

Can A-DROP help predict the need for mechanical ventilation?

While A-DROP was primarily validated as a mortality prediction tool, higher scores are associated with increased need for mechanical ventilation. In the COVID-19 pneumonia validation study, mechanical ventilation rates were 1.4% (mild), 46.7% (moderate), 78.3% (severe), and 100% (extremely severe). Similar trends have been observed in non-COVID CAP cohorts, though with generally lower absolute rates. A-DROP score at admission can therefore provide a signal regarding the likelihood of respiratory failure requiring ventilatory support, which is clinically useful for early ICU consultation and resource allocation, though it should not be used as the sole decision criterion for intubation.

How does A-DROP perform in patients with chronic kidney disease (CKD)?

Patients with chronic kidney disease have elevated baseline BUN and creatinine levels not related to dehydration or acute illness. In these patients, the dehydration criterion of A-DROP (BUN 21 mg/dL or higher) may be chronically positive regardless of their current hydration status, leading to potential score inflation. Clinicians should note a patient's baseline renal function and interpret BUN in the context of known CKD. An acute rise in BUN above baseline may be more clinically meaningful than an absolute value in this population. Some clinicians apply clinical dehydration assessment rather than relying on BUN in CKD patients when the BUN is elevated solely due to underlying renal disease.

What is the difference between A-DROP and the modified A-DROP score?

The modified A-DROP score was proposed in research studies (including a study from Saitama Medical University) as an extension of the original five-parameter A-DROP that adds respiratory rate and/or comorbidity burden. The original A-DROP score uses exactly five binary parameters (A, D, R, O, P) for a total possible score of 0–5. The modified version incorporates additional variables in an attempt to improve predictive accuracy, particularly for specific pneumonia subtypes such as aspiration pneumonia. However, validation studies have found that the modified A-DROP does not consistently add significant prognostic value over the original in aspiration pneumonia. The original five-parameter A-DROP score is the standard version used in JRS guidelines and clinical practice.

What should I do if my patient scores 0 but looks very unwell?

Clinical severity scores are decision-support tools, not rigid algorithms. If a patient scores 0 on A-DROP but appears seriously ill to the clinician - with marked distress, rapid deterioration, inability to maintain oral intake, significant comorbidities, or absence of social supports for outpatient monitoring - hospitalization remains appropriate and potentially life-saving. A-DROP provides a structured baseline assessment, but the treating clinician's gestalt, informed by training and experience, should take precedence when it conflicts with the numerical score. Document your clinical reasoning clearly whenever your management decision diverges from the score-based recommendation.

Are there any scoring systems that outperform A-DROP for pneumonia severity?

The PSI (Pneumonia Severity Index) consistently achieves slightly higher AUC values for 30-day mortality than A-DROP (typically 0.85–0.89 vs. 0.80–0.85 for A-DROP), owing to its incorporation of 20 variables. More complex scores integrating biomarkers such as procalcitonin, lactate, or CRP with clinical variables have demonstrated incremental improvements in some research settings. The SMART-COP score adds albumin, oxygen, respiratory rate, and heart rate to standard variables and has shown good discrimination, particularly for predicting the need for intensive respiratory or vasopressor support. However, A-DROP's advantages are its simplicity, speed of calculation, and validated performance across diverse clinical settings - making it a pragmatic first-line tool.

What is the formula for converting urea mmol/L to BUN mg/dL for A-DROP?

The conversion formula is: BUN (mg/dL) = Urea (mmol/L) x 2.8. Conversely, Urea (mmol/L) = BUN (mg/dL) / 2.8. The A-DROP dehydration threshold of 21 mg/dL BUN therefore corresponds to approximately 7.5 mmol/L urea. Laboratories in many countries outside North America report urea rather than BUN, so this conversion is essential for correct A-DROP scoring. Always confirm the units displayed on your patient's laboratory report before applying the threshold.

Conclusion

The A-DROP score is a validated, simple, and clinically effective tool for assessing the severity of community-acquired pneumonia. By incorporating five dichotomous parameters - age, dehydration, respiratory failure, orientation disturbance, and hypotension - it generates a score from 0 to 5 that maps directly onto four severity categories with clear management implications: outpatient care (score 0), hospitalization (scores 1–2), intensive inpatient management (score 3), and ICU-level care (scores 4–5).

Originally developed by the Japanese Respiratory Society as a modification of the CURB-65 score, A-DROP has been validated across multiple patient cohorts worldwide including in East Asia, Southeast Asia, and Europe. Its discriminatory accuracy for 30-day mortality, with AUC values typically around 0.83–0.85, is comparable to CURB-65 and somewhat lower than PSI, but its simplicity and the clinical accessibility of its parameters make it an excellent routine triage tool in diverse healthcare settings.

As with all clinical decision support tools, A-DROP performs best when integrated with comprehensive clinical assessment. Factors not captured by the score - including comorbidity burden, trajectory of illness, social context, and local microbiological epidemiology - must inform the final management decision. This calculator is intended to facilitate rapid, accurate A-DROP scoring and supports high-quality clinical reasoning at the bedside. Always consult qualified healthcare professionals for medical decisions.